Canaccord Genuity Maintains Buy on ADMA Biologics, Lowers Price Target to $18

Benzinga Newsdesk www.benzinga.com Negative 50.1%

Neg 50.1% Neu 0% Pos 0%

Canaccord Genuity analyst Gary Nachman maintains ADMA Biologics (NASDAQ:ADMA) with a Buy and lowers the price target from $21 to $18.